TuisVBIVQ • OTCMKTS
add
VBI Vaccines Inc
Vorige sluiting
$0,00050
Dagwisseling
$0,00050 - $0,00060
Jaarwisseling
$0,00020 - $0,051
Markkapitalisasie
7,17 k USD
Gemiddelde volume
56,23 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
OTCMKTS
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 1,21 m | 150,31% |
Bedryfskoste | 10,24 m | -37,68% |
Netto inkomste | -17,90 m | 35,50% |
Netto winsgrens | -1,47 k | 74,23% |
Wins per aandeel | — | — |
EBITDA | -11,26 m | 40,75% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 12,60 m | -68,82% |
Totale bates | 75,44 m | -41,27% |
Totale aanspreeklikheid | 80,91 m | -3,03% |
Totale ekwiteit | -5,47 m | — |
Uitstaande aandele | 28,68 m | — |
Prys om te bespreek | -0,00 | — |
Opbrengs op bates | -36,18% | — |
Opbrengs op kapitaal | -55,53% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -17,90 m | 35,50% |
Kontant van bedrywe | -11,77 m | 45,65% |
Kontant van beleggings | -151,00 k | 71,72% |
Kontant van finansiering | 843,00 k | — |
Netto kontantverandering | -11,09 m | 50,13% |
Beskikbare kontantvloei | -4,40 m | 70,09% |
Meer oor
Variation Biotechnologies Inc., also known as VBI Vaccines Inc., is a biopharmaceutical company, headquartered in Cambridge, Massachusetts, with research facilities in Ottawa, Ontario, Canada, and a research and manufacturing site in Rehovot, Israel. Its Ottawa facility has approximately thirty researchers working with National Research Council of Canada to produce a COVID-19 vaccine—VBI-2902. In August VBI received CA$56 million from the Government of Canada to prepare its vaccine for clinical trials by the end of 2020. The company's CEO, Jeff Baxter, said that VBI-2902 is cheaper to produce than other vaccines. Wikipedia
Gestig
1965
Webwerf
Werknemers
135
